FOR INVASIVE INFECTIONS

SUCH As SEPSIS

How HelixBind is Changing Care

Revolutionizing CARE

HelixBind is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis.

 

Its novel platform provides faster, more accurate, and more informative microbiology results, assisting clinicians in precisely identifying bloodstream infections and developing personalized antimicrobial interventions for infected patients.

 

Our approach can improve outcomes, save lives, and reduce the spread of antimicrobial resistance.

HelixBind in the News

HelixBind is growing and actively looking for talented individuals.

Explore HelixBind Technology

The Challenge of Sepsis

Sepsis, caused by a severe immune response to a bloodstream infection, is a major global health crisis.

 

Every year in the US, there are 1.7M cases, and more than 270,000 of those patients will not survive. Globally the situation is more dire, with 30M annual cases leading to well over 6M deaths.

 

Prognosis for septic patients deteriorates hourly. Fast and accurate identification and characterization of the infection is crucial so physicians can initiate the appropriate antimicrobial treatment as soon as possible.

identify the infection faster

HELIXBIND 

RESULTS IN 3 HOURS

Traditional blood culture test

RESULTS IN 2-3 DAYS

HelixBind results may help guide appropriate clinical decisions and select the best treatment options long before culture results become available. 

CONTACT HELIXBIND

 

HelixBind, Inc.
181 Cedar Hill Street
Marlborough, MA 01752 

 

For general inquiries, contact us at: 
info@helixbind.com
508-460-1028

 

For partnerships and business development:
bd@helixbind.com

For press:

media@helixbind.com

Together we can improve outcomes, save lives, and reduce the spread of antimicrobial resistance.